Approval · Notice of Compliance 36670 · 2026
TEVA-GABAPENTIN: Notice of Compliance 36670
Issued January 2, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36670
- Date
- January 2, 2026
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Replacement of a manufacturing site and/or manufacturer involving production of the drug substance. Change in the manufacturing process for the drug substance. Change in the composition of a dosage form. Replacement of a drug product manufacturing site and/or manufacturer involving production. Change in the drug product manufacturing process. Update to package labels. Update to Product Monograph (to align with CRP approved PM)
- Canadian reference product
- NEURONTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-GABAPENTIN | Not yet assigned | — |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP
- GABAPENTIN 600 MG per TAB
- GABAPENTIN 800 MG per TAB